Vaccines, Blood & Biologics
Record of Telephone Conversation - Cervarix, June 19, 2008
System Info - 94741 SHONE, DEANNA 20-May-2009 17:34:22 SHONEDE
RECORD OF TELEPHONE CONVERSATION
Submission Type: Original Application Submission ID: 125259/0 Office: OVRR
Product:
Human Papillomavirus Vaccine, AS04 Adjuvant-Adsorbed
Applicant:
GlaxoSmithKline Biologicals
Telecon Date/Time: 19-JUN-2008 12:00 AM Initiated by FDA? Yes
Telephone Number:
Communication Categorie(s):
Advice
Author: HELEN GEMIGNANI
Telecon Summary:
Email: Communication BLA 125259/0
FDA Participants:
Non-FDA Participants:
Trans-BLA Group: No
Related STNs: None
Related PMCs: None
Telecon Body:
From: Gemignani, Helen S
Sent: Thursday, June 19, 2008 6:47 AM
To: 'Matt.Whitman@gsk.com'
Cc: 'Sharon.W.Shapowal@gsk.com'
Subject: June 19 Communication BLA 125259/0 - Upload to EDR
Matt,
We have the following items to present to GSK for brief discussion at our meeting on Tuesday:
1) CBER requests that safety reports submitted to IND -b(4)-, after December 31, 2007, also be submitted to the BLA 125259.
2) CBER requests that monthly updates of number of doses distributed of Cervarix by country (EU, Mexico, Australia, Singapore, and Philippines) be submitted to the BLA.
Helen Sullivan Gemignani
Regulatory Project Manager
Division of Vaccines and Related Products Applications
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research
Food and Drug Administration
(301) 827-3070







